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Introduction
Prostate cancer (PCa) is the most common non-cutaneous male cancer and the second highest cause of cancerrelated deaths in Western society [1] . PCa mortality results from bone and lymph node metastasis and the progression from androgen-dependent to androgen-independent PCa cell growth [2] . The disease is heterogeneous in terms of grade, oncogene/tumor suppressor gene expression, genetics, and its molecular, cellular and hormonal profile is complex [1] . These alterations and heterogeneity result in the failure of androgen ablation therapy and chemotherapy, which are major therapeutic modalities for advanced PCa [3] . Therefore, considerable efforts are directed towards developing treatment strategies targeting receptors that are a part of the molecular circuitry controlling tumor growth.
Adrenoceptor
In PCa, the involvement of a wide range of G-protein coupled receptors (GPCRs) has been described [4] . The α 1 -adrenoceptors (α 1 -ARs) are of particular interest given their role in prostate function, and use as a therapeutic target. A recent comprehensive review of prostatic α 1 -ARs outlines the complex signaling pathways and additional GPCRs that this receptor can interact with [5] . Currently, the recognized subtypes of α 1 -ARs are α 1A , α 1B , α 1D [6] . α 1A -AR subtypes are the main prostate receptors and predominate in prostate stroma. α 1D -AR subtype is also found in the stroma whereas α 1B -AR is mainly found in the epithelium [7] . Functional studies suggest a predominance of α 1 -ARs which have low affinity for the quinazoline drug, Prazosin, and these have been classed as α 1L -AR, a functional phenotype of α 1A -adrenoceptor, in mouse prostate [8] .
The role of α 1 -ARs in human prostate is undisputed and therefore, is the most commonly targeted GPCR in the prostate. The α 1 -AR antagonists belonging to quinazoline family of drugs have therapeutic benefit in PCa as they induce apoptosis in the epithelial and smooth muscle cells of the prostate without affecting their proliferative capacity [9] [10]. Therapeutically, quinazolines decrease the incidence of PCa by 31.7% [11] . Evidence highlights the emerging therapeutic significance of two quinazoline drugs, Terazosin and Doxazosin as antitumor agents in PCa therapy. Doxazosin mesylate (brand name: Cardura), a subtype non-selective α 1 -adrenoceptor antagonist, promotes smooth muscle relaxation. Doxazosin has also been documented to induce apoptosis and anoikis in PCa cells, both in vitro and in vivo [12] . The apoptotic activity of this quinazoline antagonist is independent of: 1) ability to antagonize α 1 -AR; and 2) the hormone sensitivity of cells (i.e. androgen dependency) but dependent upon number and distribution of smooth muscle cells in the tissue [9] . It induces apoptosis by a) increasing caspase-3 activity in a concentration and time dependent manner which activate intracellular cascade promoting anoikis and subsequently, apoptosis; b) cleavage of focal adhesion kinases (FAK), a non-receptor tyrosine kinase mediating cell proliferation and migration, by caspases and c) decreasing Akt phosphorylation which has been shown to interfere with the apoptotic action of doxazosin [13] [14].
Endocannabinoids
Several studies have evaluated the role of the endocannabinoid system, consisting of classic cannabinoid receptors, CB1 and CB2, two endogenous ligands (anandamide and 2-arachidonoylglycerol) and several enzymes required in their production and degradation, in different PCa tissue/cell lines [15] . High CB1 receptor immunoreactivity score in PCa tissue was found to be associated with PCa severity and outcome [16] . Also, CB2 receptor expression was demonstrated in multiple PCacell lines (PC-3, DU-145, LNCaP, CWR22Rv1 and CA-HPV-10) [17] - [21] . However, role of a putative cannabinoid receptor GPR55, a 319-amino acid multi-pass membrane protein phylogenetically distinct from CB1 and CB2, in tumor progression suggests its importance as a possible cancer biomarker. High levels of GPR55 have been associated with aggressive cancers [22] and tumor angiogenesis [23] .
We have previously shown co-localization between T1117, a fluorescent form of the cannabinoid CB1 receptor antagonist AM251, which showed binding affinity for GPR55 [24] and BODIPY FL-Prazosin (QAPB), a fluorescent ligand for all α 1 -AR subtypes [25] in vascular tissue indicating their possible interaction in the cardiovascular system. Since tissue distribution of GPR55 overlaps significantly with α 1 -AR in prostate, and GPR55 shares similar pharmacology with the classical cannabinoid (CB1) receptors [26] , we investigated the degree of heterogeneity and possibility of interaction between α 1 -AR and GPR55 by examining their distribution and co-localization in vitro using two commonly used prostate carcinoma cell lines; LNCaP and PC-3. The LNCaP and PC-3 cell lines were selected as they display appropriate cellular characteristics and are widely used to model androgen-dependent early stage PCa and androgen-independent later refractory stage disease, respectively. Importantly, our findings provide preliminary evidence of co-localization and possible interaction between α 1 -AR and GPR55 and its physiological importance in neoplastic prostatic cell in vitro which has never been studied prior to this study.
Materials and Methods

Materials
Stock concentrations of fluorescent ligands were dissolved in dimethyl sulphoxide (DMSO), and diluted in distilled water as required. Ligands were obtained from the following sources: BODIPY FL-Prazosin (QAPB) and Syto 62 from Invitrogen (Invitrogen Ltd., Paisley, UK); Tocrifluor T1117 (N-(piperidin-1-yl)-5-(4-(4-(3-(5-carboxamidotetramethylrhodaminyl) propyl)) phenyl)-1-(2,4-dicholrophenyl)-4-methyl-1H pyrazole-3-carboxamide) from Tocris (Bristol, UK) and Doxazosin from Pfizer (Sandwich, UK).
Cell Culture
The human androgen-insensitive, PC-3 (ATCC: CRL-1435) and androgen-sensitive, LNCaP (ATCC: CRL-1740) prostatic carcinoma cell lines were obtained from American Type Culture Collection repository. Cells were cultured in the appropriate media recommended by the supplier supplemented with 10% Fetal Bovine Serum (FBS), Penicillin-Streptomycin (Pen-Strep) and L-Glutamine in a humidified incubator at 37˚C, 95% O 2 and 5% CO 2 until confluent. Upon attaining confluence, the cells were trypsinized and rinsed in media and PBS. Subsequently, cells were re-suspended and plated to glass coverslips 24 hours before use.
Confocal Analysis
BODIPY FL-Prazosin (QAPB, 0.1 μM) and Tocriflour (T1117, 0.1 μM) were applied in combination to determine the receptor expression and co-localization in a) control untreated PC-3 and LNCaP cells and LNCaPderived spheroids (24 hours) and b) PC-3 cells under chronic doxazosin treatment (6 weeks; 1 μM) allowed to regrow in drug-free media (2 weeks). Incubation media also included a fluorescent nuclear stain Syto 62 (1 μg/ml). Cell images are representative of at least three independent experiments in all cases.
Microscopic Examination
Cells were imaged using a Bio-Rad Radiance 2100 Confocal Laser Scanning Microscope (CLSM) using either an oil immersion lens 20× (NA 0.75) or 40× objective (NA 1.0). The CLSM was fitted with an argon ion, Green Helium Neon (HeNe) and red diode laser. In all comparative studies, laser intensity and photomultiplier tube (PMT) settings were identical. Fluorescent ligands were imaged as follows: QAPB (ex 488 nm, em 515 nm); T1117 (ex 543 nm, em 590 nm) and Syto 62 (ex 637 nm, em 660 nm). Multi-channel images are displayed as merged channels. Detailed analysis methods have previously been published [27] .
Data Analysis
Data was collected, recorded and quantified using ImageJ 1.44p. Co-localization was quantified using the JACoP plugin for ImageJ and expressed as a Pearsons Correlation between two fluorophores generated from n = 4 for PC-3 cells and n = 5 for LNCaP cells. Graphs were drawn using GraphPad PRISM 5.0. Data was expressed as mean ± SEM (Standard Error Mean) of at least 3 independent experiments. Statistical tests such as students T-tests were carried out and significance was defined as P < 0.05. Figure 1 shows the binding pattern of QAPB and T1117 in PC-3 and LNCaP cells (control). In control cell population, heterogeneity extended to the expression of both α 1 -ARs and GPR55. A spectrum of phenotypes was observed within the cell population, from those expressing predominantly α 1 -AR to those harboring predomi- nantly GPR55 (Figure 1(c) ). Importantly, it was apparent that PC-3 cells do not simply express α 1 -ARs and GPR55 in equal proportions. A small proportion of cells had both α 1 -ARs and GPR55 in relatively equal numbers reflected by the yellow fluorescence indicating a degree of co-localization of QAPB and T1117 (Figure  1(d) ). LNCaP cells (in some but not all) (Figure 1(a) ) and spheroids (Figure 1(b) ) also demonstrated clear degree of co-localization between α 1 -AR and GPR55. Co-localization (correlation analysis) of QAPB and T1117 binding revealed a stronger correlation in LNCaP (0.87 ± 0.03) cells vs PC-3 (0.63 ± 0.02) cells. Interestingly, T1117 binding was always associated with the long processes and cell tips of LNCaP cells (Figure 1(a) ).
Results
Co-Localization of Adrenergic and Cannabinoid Binding Sites in Prostate Cancer Cells
Chronic Doxazosin Treatment Elicits Upregulation of Intracellular α1-AR and GPR55 Expression, Accompanied by Stimulated Growth of PC-3 Cells
The even distribution of binding sites, in certain areas and apparent co-localization of QAPB and T1117 in control PC-3 cells suggested co-expression and possibility of strong physical/functional association between the two receptors. To determine whether the functional antagonism of α 1 -AR might result in altered GPR55 expression, ligand binding studies were performed in cells that received 1 µM doxazosin treatment for 6 weeks and returned to drug-free media for 2 weeks. The QAPB and T1117-binding induced fluorescence were determined in doxazosin-treated PC-3 cells normalized against fluorescence seen in untreated cells. Chronic administration of doxazosin resulted in significant (P < 0.05) increase in the fluorescence induced by QAPB binding suggesting upregulation in α 1 -AR (Figure 2(a) ). T1117-binding induced fluorescence was significantly higher (P < 0.01) following chronic treatment with the α 1 -antagonist (Figure 2(b) ). Sample cells are shown for comparison (Figure 2(c), Figure 2(d) ). 
Discussion
In recent years, a wealth of information describing the molecular mechanics of GPCR cycle involving agonist activation, internalization, downregulation and sequestration have been obtained. In addition, significant amount of evidence has highlighted the importance of GPCR dimerisation and co-localization that may alter receptor function, pharmacology or regulatory properties [28] . However, heterodimerisation dynamics and its generality in controlling receptor expression are not widely explored. Fluorescent ligand binding in vitro in PC-3 and LNCaP cells and LNCaP-derived spheroids demonstrated clear degree of co-localization (in some but not all cells) between α 1 -AR and GPR55. Homodimerisation and more selective heterodimerisation between individual α 1 -AR subtypes have been reported [29] . Assays showing functional interactions between cannabinoid and adrenoceptor ligands have, in fact, confirmed that adrenoceptor heterodimerisation may extend beyond αα and αβ interactions [24] . Although the resolution of current fluorescence-based study was insufficient to confirm the existence of α 1 -AR and GPR55 heterodimer, it does indicate their co-localization which is a pre-requisite of dimerization. In addition, evidence from recent molecular pharmacological studies has shown that co-expressed receptors can interact [26] [30] [31] . It can be hypothesized that co-localized α 1 -ARs and cannabinoid together potentiate the action of neurotransmitters in the prostate since the autonomic nervous system plays an important role in prostatic functions [32] . The co-localization of α 1 -ARs and GPR55 suggest a new paradigm for synergism in which interactions may be either between cells or involve converging intracellular signaling processes.
In PCa cells, fluorescent ligand binding studies showed binding sites for both T1117 and QAPB in different cellular locations (Figure 1) . The binding of QAPB appeared to be more punctuate, both on the cell surface and intracellularly whereas binding sites for T1117 were more diffuse as seen earlier from the studies on vascular endothelium [24] . This pattern of binding allowed the classification of "subtype-rich" cells which could be classed as either expressing predominantly α 1 -AR or predominantly GPR55. The presence of 'subtype-rich' cells was also observed in PC-3 cells. The significance of this is currently unknown, but it suggests that a subpopulation of cells have a preferred receptor expression profile in respect of GPCR's.
Upregulation of intracellular α 1 -AR observed in PC-3 cells following removal of chronic α 1 -AR antagonism can be considered an adaptive response to chronic administration of doxazosin. This adaptive change may manifest as withdrawal response after long-term α 1 -AR antagonist use and can explain "α 1 -AR blocker withdrawal syndrome" as an aftermath of chronic stimulation of α 1 -AR. Aarons et al. (1980) have already reported this common outcome of an adaptive response to long-term β-AR antagonist use via upregulation of tissue β-ARs [33] . Although chronic doxazosin treatment has shown to alter α 1 -AR properties in rat prostate [34] [35] , to our knowledge, there is no report of withdrawal response, via α 1 -AR upregulation, due to chronic administration of doxazosin in PCa cells.
In the present study, novel interaction between α 1 -AR and GPR55 was identified in vitro in control untreated and doxazosin-treated PC-3 cells. The apparently high expression of intracellular α 1 -AR in PC-3 cells showed that chronic doxazosin-induced response had an α 1 -AR component. This was expected; intriguingly, robust intracellular T1117 binding-fluorescence suggestive of GPR55 upregulation was also observed in these cells. This suggests that co-expression of α 1 -AR tempered the activity of GPR55 resulting in a dramatic increase in its intracellular expression in heterologous cells. It is possible that functional and perhaps physical association with α 1 -AR leads to changes in the localization of GPR55 to "active" areas in the intracellular compartment of a cell enriched with signaling molecules. The pre-requisite of this event is that the two receptors should be in close proximity, influencing their ability to transduce signals. Our co-localization study supports such a notion. In addition, our observation that PC-3 cells, high in GPR55, grow at a furious rate when returned to drug-free media (data not shown) supports our hypothesis that in a clinical setting, removal of α 1 -antagonism and the resultant stimulation of α 1 -AR may allow lysophosphotidylinositol (LPI), an endogenous natural ligand for GPR55 synthesized intracellularly from membrane phosphoinositols by phospholipase A2 (PLA2), formation via activation of PLA (2) to stimulate GPR55-mediated accelerated proliferation. A link between α 1 -AR stimulation and activation of PLA (2) has been reported [36] and if this could be demonstrated in prostatic smooth muscle then we would have a direct link between α 1 -AR stimulation and LPI production. The growth aspect is further substantiated by our observation of high levels of T1117 binding sites in the long processes of LNCaP cells. It therefore is plausible that complex functional interaction between α 1 -AR and GPR55 exist whereby α 1 -AR antagonism directly affects GPR55 functionality by overexpression after chronic doxazosin treatment to support tumorigenesis by promoting cell growth and drug resistance. Therefore, the α 1 -ARs\GPR55 ratio could identify the metastatic prognosis of PCa cells and may serve as a useful biomarker or predictor of metastatic PCa. If our hypothesis is correct, then using carefully constructed, stable, non-toxic fluorescent ligands for the receptors, the number of 'hot' cells can be determined in a biopsy by clinicians/uropathologists to monitor the efficacy of anticancer therapy which the individual is undergoing and gauge the potential/progression to aggressive PCa. These results present both α 1 -ARs and GPR55 and catecholamines as potentially significant targets for specific therapeutic modalities for treating PCa.
Conclusion
The present study suggested an interaction between α 1 -AR and GPR55 via co-localization/dimerization providing rationale for further studies on mechanisms of cross talk between different subfamilies of GPCRs. These results open a new avenue of research oriented on delineating direct physical and functional interactions between the cannabinoid and adrenergic systems that were primarily attributed to only CB1 receptor mediated presynaptic inhibition of noradrenergic transmission [37] - [40] . We suggest, therefore, in the light of our findings and the wide, overlapping distribution of α 1 -AR and GPR55, re-evaluation of interactions between adrenergic and GPR55 systems in cells and tissues that co-express both using higher resolution techniques with fluorescent ligands. In addition, our finding that the α 1 -AR antagonist doxazosin alters GPR55 receptor number in cells endogenously expressing both α 1 -AR and GPR55 needs to be studied in vivo due to the potential clinical significance of doxazosin in suppressing prostate tumourigenicity [6] . The recent observation that GPR55 is expressed in PCa cell line [41] , suggests that some of the anti-tumor effects of α 1 -AR antagonist [6] may be the result of indirect action on GPR55 in addition to the blockade of α 1 -AR. However, the unexpected, novel "GPR55" phenomenon finding, possibly conferring the properties of tumor growth and drug resistance, demonstrates the significant impact of α 1 -AR antagonists, particularly, doxazosin, in prostate carcinogenesis. To our knowledge, the current study in PC-3 cells is the first demonstration that chronic doxazosin treatment affects GPR55 expression. Since GPR55 has emerged as a lipid-sensitive modulator of oncogenesis, undoubtedly, pharmacology of LPI-GPR55 autocrine signaling system warrants focused research to develop novel therapeutics targeting the protein or its ligand for the purposes of inhibiting cancer growth and limit the risk of metastases. Moreover, studies need to be designed to investigate any association between GPR55 expression and other membrane receptors as well as with cancer remission, relapse or resistance following treatment with various chemotherapeutic inhibitory agents.
